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Replication fork reversal triggers fork degradation
in BRCA2-defective cells
Soﬁja Mijic1, Ralph Zellweger1, Nagaraja Chappidi1, Matteo Berti1, Kurt Jacobs1, Karun Mutreja1,
Sebastian Ursich1, Arnab Ray Chaudhuri2,3, Andre Nussenzweig2, Pavel Janscak1 & Massimo Lopes1
Besides its role in homologous recombination, the tumor suppressor BRCA2 protects stalled
replication forks from nucleolytic degradation. Defective fork stability contributes to
chemotherapeutic sensitivity of BRCA2-defective tumors by yet-elusive mechanisms. Using
DNA ﬁber spreading and direct visualization of replication intermediates, we report that
reversed replication forks are entry points for fork degradation in BRCA2-defective cells.
Besides MRE11 and PTIP, we show that RAD52 promotes stalled fork degradation and
chromosomal breakage in BRCA2-defective cells. Inactivation of these factors restores
reversed fork frequency and chromosome integrity in BRCA2-defective cells. Conversely,
impairing fork reversal prevents fork degradation, but increases chromosomal breakage,
uncoupling fork protection, and chromosome stability. We propose that BRCA2 is
dispensable for RAD51-mediated fork reversal, but assembles stable RAD51 nucleoﬁlaments
on regressed arms, to protect them from degradation. Our data uncover the physiopatho-
logical relevance of fork reversal and illuminate a complex interplay of homologous recom-
bination factors in fork remodeling and stability.
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BRCA1 and BRCA2 genes represent paradigmatic examplesof tumor suppressors, linking genome instability,and cancer susceptibility1. Although several nuclear and
cytoplasmic functions have been described for these proteins,
mutations predisposing to cancer predominantly affect their
common function in homologous recombination (HR). BRCA2
biochemical function in HR has been linked to the replacement of
the main single-stranded DNA-binding protein RPA with the
central recombination factor RAD51, which channels extended
ssDNA regions for strand exchange reactions1, 2. The HR
function of BRCA2 has been mostly studied in response to
double-strand breaks (DSBs). As a result, both the cancer
predisposition and the effectiveness of certain chemotherapeutic
drugs associated with BRCA2 deﬁciencies have long been linked
to the DSB-repair defect3. However, recent work has uncovered a
second, genetically separable function for BRCA2 in protecting
stalled replication forks from extensive nucleolytic degradation4.
This concept was later extended to several additional HR factors,
as well as factors mutated in the cancer predisposition syndrome
Fanconi anemia (FA)5. While controlled nucleolytic degradation
of stalled replication forks likely plays a physiological role to
tolerate replication stress, uncontrolled fork degradation upon
HR/FA defects is detrimental for genome stability and affects
cellular resistance to replication inhibitors4, 6–8. Most recently,
this uncontrolled fork degradation—as opposed to the classical
DSB repair defect—was linked both to the lethality of BRCA2-
defective embryonic stem cells and to the exquisite sensitivity of
BRCA-defective cells to certain chemotherapeutic treatments,
elucidating a novel crucial mechanism of therapy resistance of
BRCA-defective tumors9. It is thus of clinical relevance to
investigate the detailed molecular mechanisms mediating or
limiting fork degradation in response to chemotherapeutic
treatments.
Recent visualization of replication intermediates in human cells
has revealed replication fork reversal—that is, the conversion of
replication forks into four way junctions by strand exchange
reactions—as a global, evolutionary conserved cellular response to
various conditions of replication stress, such as oncogene acti-
vation, chemotherapeutic treatments, and replication of genomic
sequences intrinsically prone to form secondary structures10–13.
Reversed forks were also recently shown to protect genome
integrity in unperturbed embryonic stem cells (ESCs), which
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Fig. 1 Stalled replication forks can reverse in the absence of BRCA2, but are targeted by nucleolytic degradation. a, c Electron micrographs of representative
replication forks from RPE-1 cells: parental (P) and daughter (D) duplexes. a The black arrow indicates the regressed arm (R); the four-way junction at the
reversed fork is magniﬁed in the inset. c The white arrow points to a ssDNA region at the fork. Scale bar, 200 nm (= 460 bp), 40 nm (= 92 bp) in the
inset. b Left panel: frequency of reversed replication forks isolated from mock-depleted (siLuc) and BRCA2-depleted (siBRCA2) RPE-1 cells upon optional
5 h treatment with 4 mM HU; where indicated, 50 μM mirin was added 1 h before HU treatment (6 h total treatment). The number of replication
intermediates analyzed is indicated in parentheses. The graph depicts mean and SD from three independent EM experiments, blinded to the investigator.
The results of the individual biological replicates are in Supplementary Table 1. Right panel: western blot analysis of BRCA2 levels in siLuc and siBRCA2
RPE-1 cells, 48 h after transfection. TFIIH, loading control. d Graphical distribution of ssDNA length at the junction (white arrow in Fig. 1c) in siLuc and
siBRCA2 RPE-1 cells optionally treated with 4 mM of HU for 5 h and 50 μM of mirin for 6 h. Only molecules with detectable ssDNA stretches are included
in the analysis. The lines show the median length of ssDNA regions at the fork in the speciﬁc set of analyzed molecules. Statistical analysis: Mann–Whitney
test; ns, not signiﬁcant; *P< 0.1; **P< 0.01; ***P< 0.001; ****P< 0.0001. The number of analyzed molecules is in brackets
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experience endogenous replication stress as a consequence of
their accelerated cell cycle progression14. Fork reversal was shown
to require the central recombinase RAD5111, suggesting
that classical HR factors mediate strand exchange reactions at
replication forks. Furthermore, reversed forks can be restarted by
RECQ1-dependent branch migration15, but can also undergo
controlled resection by DNA2/WRN7. The involvement of HR
factors in reversed fork formation and processing suggests that
fork reversal might be mechanistically linked to the extensive fork
degradation observed in BRCA2-defective cells.
Here, we show that replication fork reversal is required for fork
degradation in BRCA2-defective cells, as regressed arms act as
entry points for MRE11-dependent degradation. Furthermore, we
clarify the differential contribution of RAD51 and RAD52 in
different steps of fork remodeling and protection. Finally, we
provide evidence that, albeit priming fork degradation, reversal of
stalled forks is essential to prevent excessive chromosomal
breakage in BRCA2-defective tumor cells.
Results
Unstable reversed forks and extended ssDNA upon BRCA2
defects. To assess replication fork architecture during fork
degradation in BRCA2-defective cells, we visualized replication
intermediates in vivo by an established electron microscopy (EM)
method16. We treated untransformed human retinal pigmented
epithelial (RPE-1) cells with hydroxyurea (HU) to deplete
nucleotides and stall replication forks. As previously shown11, the
HU treatment led to signiﬁcant accumulation (20%) of reversed
replication forks, but their frequency was decreased twofold upon
BRCA2 depletion by small interfering RNA (siRNA) (Fig. 1a, b;
Supplementary Table 1). MRE11 inhibition by mirin17 had no
signiﬁcant effect on reversed fork frequency in untreated cells or
in HU-treated wild-type cells, but restored full fork reversal levels
in BRCA2-depleted HU-treated cells (Fig. 1b; Supplementary
Table 1). Thus, replication forks can be effectively reversed upon
HU treatment also in the absence of BRCA2, but they are targeted
by MRE11-dependent degradation. Although we did not detect a
speciﬁc accumulation of ssDNA on regressed arms in HU-treated
BRCA2-defective cells (Supplementary Fig. 1a), extended ssDNA
stretches were observed upon BRCA2 downregulation at standard
three-way fork junctions and were suppressed by mirin treatment
in HU-treated cells (Fig. 1c, d). Shorter HU treatments also led
to reduced reversed fork frequency in BRCA2-defective cells,
but did not reveal increased ssDNA at fork junctions or regressed
arms (Supplementary Fig. 1b, c, Supplementary Table 2).
Taken together, these data suggest that nucleolytic processing in
HU-treated BRCA2-defective RPE-1 cells rapidly degrades
regressed arms and, upon prolonged treatments, continues
on newly synthesized DNA behind the fork. Whether or not
transient accumulation and/or partial resection of reversed
forks is visible by EM upon short genotoxic treatments in
BRCA2-defective cells likely reﬂects different kinetics of fork
reversal and processing in different cell lines18. These data
highlight the different resolution and limitations of DNA ﬁber
assays and EM visualization of fork remodeling and degradation,
as recently discussed19.
As PTIP depletion in mouse B cells was recently reported to
suppress fork degradation in BRCA2-defective cells by limiting
MRE11 recruitment at stalled forks9, we identiﬁed conditions
to downregulate PTIP by two different siRNAs in RPE-1 cells,
preceding long-term effects on cell cycle progression (Supple-
mentary Fig. 2a, b)20, and monitored fork degradation by
DNA ﬁbers. As reported4, 9, HU-treated BRCA2-defective cells
displayed marked degradation of nascent DNA, also by a labeling
scheme that excludes shortening of replicated tracts by
fork breakage (Supplementary Fig. 2c, d). In these conditions,
similarly to mirin, PTIP downregulation suppressed fork
degradation (Supplementary Fig. 2c) and restored wild-type
levels of reversed forks and ssDNA in BRCA2-defective
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Fig. 2 BRCA2 maintains reversed fork stability in different cell lines and upon different genotoxic treatments. a Top: schematic representation of BRCA2
protein. Green boxes: RAD51-binding BRC repeats; black box: DBD, DNA-binding domain; C-ter, yellow bar: RAD51-biding C-terminal region. Blue arrows
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number of analyzed molecules is indicated in brackets. Results of two independent EM experiments are in Supplementary Table 4. Right: western blot
analysis of BRCA2 levels in V-C8 and complemented cells. TFIIH, loading control. b EM-based analysis of reversed replication forks isolated from siLuc and
siBRCA2 (48 h) RPE-1 cells treated with 25 nM CPT for 1 h; where indicated, 50 μM mirin was added 1 h before CPT treatment (2 h total treatment). In
brackets, the total number of analyzed molecules. Results of two independent EM experiments are in Supplementary Table 5
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HU-treated cells (Supplementary Fig. 2e, f and Supplementary
Table 3). Thus, reversed forks appear as “entry points” for
extensive MRE11-dependent degradation of stalled forks in
BRCA2-defective RPE-1 cells.
Chinese Hamster BRCA2-defective cells (V-C8), previously
reported to undergo fork degradation upon HU treatment4, also
displayed reduced reversed fork levels and extended ssDNA
stretches at forks (Fig. 2a, Supplementary Fig. 3a). Mirin
treatment or complementation of these cells with WT BRCA2
restored high frequencies of reversed forks and short ssDNA
stretches at forks. However, expression of the BRCA2
phosphorylation mutant S3291A—which causes a defect in fork
integrity, but allows HR-mediated DSB repair4—failed to
complement either defect in V-C8 cells (Fig. 2a, Supplementary
Table 4 and Supplementary Fig. 3a), further linking reversed fork
instability and fork degradation upon BRCA2 defects. Notably,
reduced reversed fork frequency and extended ssDNA stretches at
forks—both effectively suppressed by MRE11 inhibition—were
also observed in BRCA2-depleted cells upon short treatments
with low dose (25 nM) of camptothecin (CPT; Fig. 2b, Supple-
mentary Table 5 and Supplementary Fig. 3b), which induces
frequent fork reversal but does not completely arrest fork
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progression11, 21. These data show that BRCA2 generally protects
reversed forks from nucleolytic degradation also in conditions of
mild replication interference, where fork degradation is difﬁcult
to monitor by DNA ﬁber assays.
Replication fork reversal is required for fork degradation. The
role of BRCA2 in fork protection was previously linked to RAD51
chromatin loading5, 22. However, RAD51 is also essential for the
accumulation of reversed forks, which appear to be the substrate for
degradation in BRCA2-defective cells (Figs. 1 and 2). To resolve this
conundrum, we analyzed fork degradation upon effective RAD51
downregulation. In contrast to BRCA2 defects4, 22, depletion of
RAD51 by two different siRNA sequences in HU-treated cells did
not lead to fork degradation and surprisingly suppressed fork
degradation in BRCA2-depleted cells (Fig. 3a, Supplementary
Fig. 4a). These data suggest that preventing fork reversal by RAD51
inactivation prevents fork degradation in BRCA2-defective
cells. Indeed, in our EM analysis, RAD51 depletion abolished
HU-induced fork reversal also in the presence of mirin and
prevented mirin-dependent restoration of reversed fork levels in
BRCA2-defective cells (Fig. 3b and Supplementary Table 6). Nota-
bly, a different genetic perturbation that was recently shown to
affect reversed fork formation in vivo23—that is, depletion of the
DNA translocase ZRANB324–26—also completely suppressed fork
degradation in BRCA2-defective cells (Fig. 3c). Reversed fork for-
mation requires the helicase, but not the nuclease activity of
ZRANB323, 24, 26. Accordingly, we found that cells expressing at
endogenous levels23 helicase-defective—but not wild-type or
nuclease-defective—ZRANB3 are resistant to fork degradation
upon BRCA2 downregulation (Fig. 3d). Furthermore, PARP inhi-
bition prior to HU treatment, which was previously reported to
prevent efﬁcient fork reversal11, also suppressed fork degradation in
BRCA2-depleted cells (Fig. 3e). Interestingly, this effect was not
reported when the PARP inhibitor was added concomitantly with
HU27. The latter conditions are likely to be initially permissive for
HU-dependent reversed fork accumulation and thus prime fork
degradation before PARP inhibition results in RECQ1-dependent
reversed fork resolution11, 15. Altogether, these results strongly
support the notion that fork reversal triggers fork degradation in
BRCA2-deﬁcient cells. PARP inhibitor and cisplatin treatments
were also recently used to link chemoresistance in BRCA2-defective
cells with restored fork stability9, 28. However, it should be noted
that this outcome requires PARP inhibition or downregulation
before BRCA2 inactivation9, 28, under which conditions the efﬁ-
ciency of fork remodeling has not been directly tested.
Fork reversal does not require stable RAD51 nucleoﬁlaments.
In light of these data and previous reports4, RAD51 seems to be
essential both for BRCA2-independent reversed fork formation
and for BRCA2-dependent protection of reversed forks from
nucleolytic degradation. Thus, different genetic manipulations
affecting RAD51 function may have diverse effects on each step of
fork remodeling, likely explaining the different fork degradation
phenotypes reportedly associated with RAD51 defects4, 22. A
dominant RAD51 mutant allele, found in FA patients, that is,
RAD51-T131P, was recently reported to destabilize RAD51
nucleoﬁlaments, by constitutive activation of RAD51 ATPase
activity, leading to ssDNA accumulation by nucleolytic proces-
sing of replicating DNA8. Upon HU treatment, these patient cells
—similarly to BRCA2-deﬁcient cells—displayed extensive fork
degradation, which was suppressed by mirin treatment (Fig. 4a).
EM analysis of RAD51-T131P cells revealed a marked reduction
in reversed fork levels, compared to wild-type counterparts,
which was also suppressed by MRE11 inhibition (Fig. 4b and
Supplementary Table 7). Together with our previous results,
these data strongly suggest that unstable RAD51 ﬁlaments in
RAD51-T131P cells are still capable of driving fork reversal, but
fail to protect reversed forks from nucleolytic degradation,
uncoupling RAD51 functions in fork remodeling and stability.
RAD52 promotes stalled fork degradation via MRE11
recruitment. As RAD51-mediated fork reversal is BRCA2-inde-
pendent, we next tested whether RAD52—which was shown to
play an essential role in the absence of BRCA2 and to assist HR
mechanisms speciﬁcally upon replication stress29–31—could assist
RAD51 in reversed fork formation and mediate fork degradation
upon BRCA2 deﬁciency. Besides its recently established role in
mitotic DNA synthesis and upon breakage of persistently stalled
forks31, 32, RAD52 is also stably recruited to chromatin in
unperturbed S phase32 and might thus participate in early events
occurring at transiently stalled replication forks. Importantly,
RAD52 depletion by two independent siRNA sequences—as well
as treatment with a speciﬁc RAD52 inhibitor32, 33—completely
abolished fork degradation in BRCA2-deﬁcient cells (Fig. 5a), in
conditions that do not drastically affect cell cycle progression
(Supplementary Fig. 4b). However, differently from RAD51
depletion, RAD52 depletion did not per se affect fork reversal, but
rather restored normal reversed fork levels in HU-treated
BRCA2-defective cells (Fig. 5b and Supplementary Table 8).
These effects are highly reminiscent of those observed for MRE11
inhibition or PTIP depletion (Supplementary Fig. 2)9 and suggest
a key role for RAD52 in driving MRE11-dependent reversed fork
processing. In line with this interpretation, RAD52 inhibition
signiﬁcantly reduced recruitment of MRE11 to HU-stalled forks
in BRCA2-defective cells, as monitored by iPOND (Fig. 5c).
Furthermore, similarly to MRE11 inhibition and PTIP depletion9,
RAD52 depletion markedly suppressed HU-induced chromoso-
mal breakage associated with BRCA2 deﬁciency (Fig. 5d). Thus,
Fig. 3 Impairing replication fork reversal prevents fork degradation in BRCA2-defective cells. a RPE-1 cells were transfected with siRNA before CldU (red)
and IdU (green) labeling (siBRCA2, 48 h; siRAD51, 24 h), followed by treatment with 4mM HU for 5 h. Left panel: levels of indicated proteins, assessed by
western blot. TFIIH, loading control. Middle panel: a representative set of DNA ﬁbers from each condition is shown. Right panel: IdU/CIdU tract length ratio
is plotted. Horizontal lines and the numbers indicate the median value. Whiskers indicate the 10–90 percentiles. At least one hundred replication forks
were analyzed for each condition. Statistical analysis: Mann–Whitney test; ns, not signiﬁcant; ****P< 0.0001. See also Supplementary Fig. 4a. b Frequency
of reversed replication forks isolated from siLuc, siBRCA2 (48 h) and siRAD51 (24 h) RPE-1 cells treated as in Fig. 1 (4 mM HU for 5 h; 50 μMmirin for 6 h).
In brackets, the total number of analyzed molecules. Results of two independent EM experiments are in Supplementary Table 6. c The indicated U2OS-
based cell lines were transfected with siRNA before CldU (red) and IdU (green) labeling (siBRCA2, 48 h; siRAD51, 24 h), followed by treatment with 4mM
HU for 5 h and DNA ﬁber spreading. Left panel: levels of indicated proteins, assessed by western blot. TFIIH, loading control. Right panel: IdU/CIdU tract
length ratio is plotted. Track length analysis and statistics as in Fig. 3a. d Stable derivatives of ZRANB3-KO U2OS cells, expressing wild-type (WT), helicase-
dead (HD), or nuclease-dead (ND) ZRANB3 at endogenous levels were transfected with siRNA for BRCA2 48 h before CldU (red) and IdU (green) labeling,
followed by treatment with 4 mM HU for 5 h. Track length analysis and statistics as in Fig. 3a. e U2OS cells were transfected with the indicated siRNAs
48 h before CldU (red) and IdU (green) labeling, followed by treatment with 4mM HU for 5 h. The PARP inhibitor olaparib (10 μM) was optionally added
2 h before CldU addition. Track length analysis and statistics as in Fig. 3a
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RAD52 is required to prime MRE11-dependent stalled fork
resection in BRCA2-defective cells. Whether the role of RAD52 in
MRE11 recruitment and reversed fork resection reﬂects its strand
exchange34, 35, single-strand annealing36, inverse RNA/DNA
strand exchange,37 or other yet uncharacterized biochemical
activities will require further investigation.
Fork reversal prevents chromosome breakage upon fork stal-
ling. Reversed forks were recently shown to protect against
genome instability during accelerated proliferation in early
embryogenesis14. We thus tested whether the reported rescue of
viability of mouse Brca2-null ESCs by PTIP depletion9 was also
related to the protection of reversed forks from nucleolytic
degradation. Upon transient downregulation of Brca2 in unper-
turbed mouse ESCs (Supplementary Fig. 4c), we observed a
decrease in the level of endogenous reversed forks, as compared
to control cells. Notably, rescuing fork degradation by
PTIP depletion restored normal frequencies of reversed forks in
Brca2-null cells (Fig. 6a and Supplementary Table 9). These data
further support a model where the essential role of key HR factors
—for example, RAD51 and BRCA2—in early embryogenesis
reﬂects their function in replication fork remodeling and
protection9, 14.
Preventing MRE11-dependent degradation by mirin treatment,
as well as PTIP or RAD52 downregulation, suppressed the
chromosomal breakage observed in HU-treated BRCA2-defective
cells (Figs. 5d and 6b)9. However, preventing fork reversal—for
example, by ZRANB3 inactivation—also suppressed nucleolytic
degradation (Fig. 3c), but rather elevated chromosomal breakage
in BRCA2-defective U2OS cells. Chromosomal breaks upon
simultaneous inactivation of ZRANB3 and BRCA2 were not
suppressed by mirin treatment or PTIP depletion, indicating that
they are not directly associated with unscheduled fork degrada-
tion (Fig. 6b), but likely with defective HR-mediated repair of
DSBs arising upon genotoxic stress in the absence of fork reversal.
Furthermore, PARP inhibition shortly before HU treatment—
which is also preventing effective fork reversal11—increased
chromosomal breakage in BRCA2-defective cells, but did not
further increase chromosome instability in ZRANB3-KO BRCA2-
defective cells, showing epistatic effects of these two means of fork
reversal impairment (Fig. 6c). Altogether, these data strongly
suggest that preventing fork degradation by abolishing fork
reversal is detrimental for genome stability in BRCA2-defective
cells, as it likely results in replication fork collapse. Thus, fork
reversal limits chromosomal breakage and genome instability at
stalled forks, providing additional evidence for the physiological
role of this global DNA transaction occurring upon replication
stress11, 13. These data also support a recent alternative model for
the speciﬁc toxicity of PARP inhibition in BRCA2-defective
tumors, where fork reversal suppression by PARP inhibitors11, 21
underlies the observed increase in fork breakage, requiring
BRCA2 classical function in DSB repair13.
Discussion
Taken together, our data reveal a complex interplay of different
HR factors in forming and processing reversed forks. We propose
that the same apparatus that mediates controlled resection of
reversed forks—to allow their effective restart—may become
deregulated in BRCA2-defective cells and mediate extensive
degradation of reversed forks (Fig. 7). Importantly, we show that
these processing events are primed by fork reversal and can
potentially occur even upon genotoxic treatments that do not
completely block replication fork progression (e.g., mild CPT
treatments), which better reﬂect clinically relevant conditions of
replication interference and are anyway strong inducers of fork
reversal21. RAD51 is clearly involved both in the formation and
in the protection of reversed forks. Therefore, the molecular
consequences of speciﬁc RAD51 mutations will likely depend on
residual fork reversal and fork protection activities in each genetic
background. Based on our data, stable RAD51 nucleoﬁlaments
are strictly required to protect regressed arms, but unstable
ﬁlaments and/or inefﬁcient loading of RAD51 on ssDNA—as in
BRCA2-deﬁcient or RAD51-T131P cells—would not impair
strand exchange reactions at replication forks (i.e., fork reversal),
probably because they do not imply extensive homology search at
a distance. It is intriguing that BRCA2 defects and this speciﬁc
RAD51 mutation are both associated with FA and it will be
crucial to extend this molecular analysis to other FA mutations.
An intriguing implication of our work is the BRCA2-
independent role of RAD51 in promoting fork reversal. This
is in principle surprising, as RPA is known to rapidly bind
ssDNA generated at forks and BRCA2 has been clearly implicated
in replacing RPA with RAD5138, in order to form a stable
nucleoﬁlament. However, previous reports have suggested
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BRCA2-independent RAD51 chromatin loading upon replication
stress9, 39. We envision several non-mutually exclusive scenarios
to explain this intriguing observation: (1) besides BRCA2-
mediated RAD51 loading at DNA ends, alternative mediators
may have evolved to assist RPA-RAD51 exchange speciﬁcally in
the context of ssDNA accumulating at a fork junction; (2) direct
displacement of ssDNA-bound RPA by RAD51 at replication
forks may be assisted by local exhaustion of free RPA40 and/or
reported direct interactions between RAD51 and the replicative
helicase;41 (3) as suggested by our data on RAD51-T131P mutant
cells, inefﬁcient and partial replacement of RPA with short and
unstable RAD51 ﬁlaments in the absence of BRCA2 may be
sufﬁcient to assist strand annealing at uncoupled forks, and thus
prime fork reversal, which is anyway assisted by other enzymatic
activities23. Uncovering the speciﬁc regulation of RAD51 activity
in fork remodeling will require extensive biochemical recon-
stitution and in vivo investigations on replication intermediates.
Another important implication of our data is that not all
genetic conditions suppressing fork nucleolytic degradation in
BRCA2-defective cells are expected to rescue genome stability and
survival to genotoxic treatments, which is relevant for informed
predictions on chemoresistance of BRCA2-defective tumors.
Based on these data, we would expect that only genetic alterations
still allowing reversed fork formation, but preventing
their degradation would truly result in resistance to classical
chemotherapeutic treatments (Fig. 7). However, due to the
involvement of several factors—such as MRE11 and, here,
RAD52—in both fork degradation and restart of collapsed
forks31, 42, a detectable decrease in chromosomal breakage due to
limited fork resection may not per se predict better recovery and
resistance to genotoxic treatments. Indeed, despite extensive
resection, BRCA2-defective cells are able to restart stalled forks4, 9
and a signiﬁcant proportion of the observed chromosomal
breaks may in fact reﬂect fork restart pathways contributing
to cell survival18. This intricate series of events likely explains
why suppression of fork degradation is observed upon transient
RAD52 downregulation in BRCA2-defective cells, although
inactivation of these genes is reportedly synthetically lethal29 and
RAD52 is actively explored as potential therapeutic target in
BRCA2-defective tumors43, 44.
In light of our data and of the structural resemblance of
regressed arms to DSBs, it is tempting to speculate that other
classical DSB processing and repair factors may play relevant
roles in replication fork remodeling, protection, and restart,
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thereby determining sensitivity or resistance to current
chemotherapeutic treatments.
Methods
Cells and cell culture. Human osteosarcoma U2OS cells, retinal pigment
epithelium RPE-1 cells and VC-8 hamster cells, V-C8 cells complemented with
human BACs (V-C8 + BRCA2 and V-C8 + BRCA S3291A)4 were cultured in
DMEM (41966-029, Life Technologies) supplemented with 10% (v/v) FBS,
100 Uml−1 penicillin, and 100 µg ml−1 streptomycin at 37 °C and 6% CO2.
Patient ﬁbroblasts RAD51-T131P and BJ foreskin ﬁbroblasts (ATCC) were grown
in DMEM (41965-039, Life Technologies) supplemented with 15% (v/v) FBS,
100 Uml−1 penicillin, and 100 µg ml−1 streptomycin at 37 °C and 6% CO28.
PL2F2 mouse ESCs were maintained in DMEM with 15% fetal bovine serum,
0.00072% β-mercaptoethanol, 100 Uml−1 penicillin, 100 μg ml−1 streptomycin, and
0.292 mgml−1 L-glutamine at 37 °C and 5% CO29. ESCs were cultured on feeder
cells (mouse embryonic ﬁbroblasts, inactivated with 10 mgml−1 mitomycin C) for
two passages, after they were transferred to feeder-free, gelatinized tissue culture
dishes (0.1% gelatin from porcine skin, Sigma).
Transfections and treatments. For knockdown experiments, cells were
transfected 20–48 h (as indicated below) prior to sample collection with the
indicated siRNA using RNAiMax transfection reagent (Life Technologies)
according to the manufacturer’s instructions:
siLuc (40 nM; 5′-CGUACGCGGAAUACUUCGAUUdTdT-3′);
siBRCA2 (48 h, 40 nM; 5′-UUGACUGAGGCUUGCUCAGUUdTdT-3′);
siRAD51#1 (24 h, 40 nM; 5′-GACUGCCAGGAUAAAGCUUdTdT-3′);
siRAD51#2 (24 h, 40 nM; 5′-GUGCUGCAGCCUAAUGAGAdTdT-3′);
siPTIP#1 (20 h, 40 nM; 5′-AAGGAAGAAGAGGAAGAGGAAdTdT-3′);
siPTIP#2 (20 h, 40 nM; 5′ UGUUUGCAAUUGCGGAUUAUUdTdT-3′);
siRAD52#1 (24 h,10 nM, ON-TARGETplus Human RAD52 (5893),
Dharmacon);
siRAD52#2 (48 h, 10 nM, s11746 (4392420), Ambion).
Mouse ESCs were passaged in feeder-free conditions and plated in 50%
standard culture medium and 50% Opti-MEM (Thermo Fisher Scientiﬁc)
containing RNAiMax transfection reagent (Life Technologies) with the mix of
following siRNAs at ﬁnal concentration of 60 nM for 48 h:
siBrca2#1 (5′-UGUUAGGAGAUUCAUCUGGdTdT-3′);
siBrca2#2 (5′-GGCCUAGUCUCAAGAACUCdTdT-3′);
siBrca2#3 (5′-GGAAUUGUAAGGUAGGCUCdTdT-3′).
BRCA2 conditional knockout cells with shRNAs against Ptip mRNA ESCs were
provided by the lab of A.N9.
The following reagents were used to treat the cells for the indicated time at the
indicated ﬁnal concentrations before collection: HU (H8627, Sigma-Aldrich) was
prepared in double-distilled H2O to obtain a 100 mM (7.6 mgml−1) stock (freshly
made); mirin (M9948, Sigma-Aldrich) was dissolved in DMSO to yield a 50 mM
stock, and aliquots were stored at −80 °C; CPT (C9911, Sigma-Aldrich) was
dissolved in DMSO to yield a 20 mM (7mgml−1) stock (freshly made); Nocodazole
(M1404, Sigma-Aldrich) was prepared in DMSO at the ﬁnal concentration of
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1 mgml−1, aliquoted, and stored at −80 °C. The Rad52 inhibitor (AICAR, A9978,
Sigma-Aldrich) was dissolved in H2O to a ﬁnal concentration of 40 mM and stored
at −20 °C. The PARP inhibitor Olaparib (AZD2281, Ku-0059436; S1060,
Selleckchem) was prepared in DMSO to obtain the concentration of 20 mM,
aliquoted, and stored at −20 °C.
Western blotting. Cells were collected using trypsin, immediately lysed using SDS
buffer (0.16 M Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 100 mM DTT, and 0.01%
bromophenol blue) and sonicated by Bioruptor (Diagenode) at 4 °C with the
highest setting for 10 min (30 s on and 30 s off cycles). The lysates were incubated
at 70 °C for 10 min and centrifuged at 13,000 r.p.m. for 7 min. Protein con-
centration in samples was measured using Nanodrop (A280). Equal amounts of
protein (50–100 μg) were loaded on a NuPAGE-Novex 3–8% Tris-Acetate or
NuPAGE-Novex 10% Bis-Tris gels (Life Technologies) and ran for 1 h, 180 V at
room temperature. Proteins were blotted for 100 min (30 V, room temperature) on
Amersham Protran 0.2 mm NC (GE Healthcare). Membranes were blocked in 5%
milk in 0.1% TBST (1 × TBS supplemented with 0.1% Tween 20) for at least 30 min
and incubated in 2% BSA with primary antibodies overnight at 4 °C. Membranes
were probed for BRCA2 (1:500, Ab-1, OP 95, EMD Millipore); RAD51 (1:1000,
H-92, sc-8349, Santa Cruz Biotechnology); RAD52 (1:1000, F-7, sc-365341, Santa
Cruz Biotechnology); PTIP (1:500, ab214732, Abcam); ZRANB3 (1:1000, 23111-1-
AP, ProteinTech); TFIIH (1:2000, S-19, sc-293, Santa Cruz Biotechnology).
Secondary antibodies were added for 1 h at room temperature (in blocking
solution). Membranes were washed three times with 0.1% TBST, 10 min each, after
primary and secondary antibody incubations and detected with ECL detection
reagent (GE healthcare). Uncropped blots for each western blot ﬁgure are provided
in Supplementary Fig. 5.
Electron microscopy analysis. The procedure was performed as recently
described16, with minor modiﬁcations described below. Following the depletion of
the protein of interest, asynchronous subconﬂuent cells were treated with 25 nM
CPT for 1 h or 4 mM HU for 5 h. Where indicated, cells were pretreated with
50 μMmirin for 1 h. Cells were collected, resuspended in PBS, and crosslinked with
4,5′, 8-trimethylpsoralen (10 μg ml−1 ﬁnal concentration), followed by irradiation
pulses with UV 365 nm monochromatic light (UV Stratalinker 1800; Agilent
Technologies). For DNA extraction, cells were lysed (1.28 M sucrose, 40 mM
Tris-HCl (pH 7.5), 20 mM MgCl2, and 4% Triton X-100; Qiagen) and digested
(800 mM guanidine-HCl, 30 mM Tris-HCl (pH 8.0), 30 mM EDTA (pH 8.0), 5%
Tween-20, and 0.5% Triton X-100) at 50 °C for 2 h in presence of 1 mgml−1
proteinase K. The DNA was puriﬁed using chloroform/isoamylalcohol (24:1) and
precipitated in 0.7 volume of isopropanol. Finally, the DNA was washed with 70%
EtOH and resuspended in 200 μl TE (Tris-EDTA) buffer. Restriction enzyme of
100 U (PvuII high ﬁdelity, New England Biolabs) were used to digest 12 μg of
mammalian genomic DNA for 4–5 h. Replication intermediates enrichment was
performed by QIAGEN Plasmid Mini Kit columns. The QIAGEN-tip 20 surface
tension was reduced by applying 1 ml QBT buffer. The columns were washed
and equilibrated with 10 mM Tris-HCl (pH 8.0), 1 M NaCl, followed by 10 mM
Tris-HCl (pH 8.0), 300 mM NaCl, respectively. DNA was then loaded onto the
columns. The columns were then washed with high NaCl solution (10 mM
Tris-HCl (pH 8.0) and 900 mM NaCl) and eluted in caffeine solution (10 mM
Tris-HCl (pH 8.0), 1 M NaCl, and 1.8% (w/v) caffeine). To purify and concentrate
the DNA, an Amicon size-exclusion column was used. DNA was then resuspended
in TE buffer. The benzyldimethylalkylammonium chloride method was used to
spread the DNA on the water surface and then load it on carbon-coated 400-mesh
copper grids. Subsequently, DNA was coated with platinum using a high
vacuum evaporator MED 020 (BalTec). Microscopy was performed with a
transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 ﬁlament; high
tension ≤120 kV) and picture acquisition with a side mount charge-coupled device
camera (2600 × 4000 pixels; Orius 1000; Gatan, Inc.). For each experimental
condition, at least 70 replication fork molecules were analyzed. DigitalMicrograph
version 1.83.842 (Gatan, Inc.) and ImageJ (National Institutes of Health) were used
to process and analyze the images.
DNA ﬁber analysis. Following the depletion of proteins of interest, cells were
sequentially pulse-labeled with 30 μM CldU (c6891, Sigma-Aldrich) and 250 μM
IdU (I0050000, European Pharmacopoeia) for 20 min and treated with HU (4 mM)
for 5 h. The cells were collected and resuspended in PBS at 2.5 × 105 cells per ml.
The labeled cells were diluted 1:5 (v/v) with unlabeled cells, and 2.5 µl of cells were
mixed with 7.5 µl of lysis buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and
0.5% (w/v) SDS) on a glass slide. After 9 min, the slides were tilted at 15–45°,
and the resulting DNA spreads were air dried, ﬁxed in 3:1 methanol/acetic acid
overnight at 4 °C. The ﬁbers were denatured with 2.5 M HCl for 1 h, washed with
PBS and blocked with 0.2% Tween 20 in 1% BSA/PBS for 40 min. The newly
replicated CldU and IdU tracks were labeled (for 2.5 h in the dark, at RT) with
anti-BrdU antibodies recognizing CldU (1:500, ab6326; Abcam) and IdU (1:100,
B44, 347580; BD), followed by 1 h incubation with secondary antibodies at RT in
the dark: anti–mouse Alexa Fluor 488 (1:300, A11001, Invitrogen) and anti–rat Cy3
(1:150, 712-166-153, Jackson ImmunoResearch Laboratories, Inc.). Fibers were
visualized (IX81; Olympus; objective lenses: LC Plan Fluor 60 × , 1.42 NA oil
Olympus BX60 microscope) and analyzed using ImageJ software. The
Mann–Whitney test was applied for statistical analysis using Prism (GraphPad
Software).
Isolation of proteins on nascent DNA or iPOND. iPOND was performed
essentially as described45. At least 1.0 × 108 of HEK293T cells were used per
sample. BRCA2 depletion was performed 2 days before EdU labeling. The RAD52
inhibitor (AICAR, 40 μM) was optionally added 2 h before 10 μM EdU labeling
(15 min), followed by 5 h 4 mM HU treatment (HU) or by 2 h 10 μM thymidine
chase (Thy-chase). Cells were cross-linked with 1% formaldehyde for 12 min at
room temperature, quenched with 0.125 M glycine and collected by scraping.
The cells were washed with PBS three times and permeabilized with 0.25% Triton
X-100/PBS at room temperature for 30 min. Before the click reaction, samples were
washed once in 0.5% BSA/PBS and once in PBS.
For the conjugation of EdU with biotin azide (Vanderbilt University,
Chemical Synthesis Core), cells were incubated with click reaction buffer (10 mM
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sodium-L-ascorbate, 10 μM biotin azide, and 2 mM CuSO4) for 2 h at room
temperature. Following the click reaction, cells were washed once in 0.5% BSA/PBS
and once in PBS. Cells were then resuspended in lysis buffer (50 mM Tris-HCl,
pH 8.0, and 1% SDS) supplemented with protease inhibitors (Roche), and
chromatin was solubilized by sonication in a Bioruptor (Diagenode) at 4 °C for
20 min (20 s pulse/40 s pause). After centrifugation at 16,100×g for 10 min, clariﬁed
supernatants were collected and diluted 1:1 (v/v) with PBS containing proteinase
inhibitor. To capture biotin-tagged nascent DNA, each sample was incubated at
4 °C o/n in the dark with streptavidin-agarose beads (Novagen, D00148073). Bead
slurry of 200 μl was used per 1 × 108 cells. After binding, beads were washed with
lysis buffer, followed by one time wash with 1 M NaCl and two times with lysis
buffer. Captured proteins were eluted by boiling beads in 2 × SDS Laemmli Sample
Buffer (0.4 g SDS, 2 ml 100% glycerol, 1.25 ml 1M Tris pH 6.8, and 0.01 g
bromophenol blue in 8 ml H2O) for 25 min at 95 °C. Proteins were resolved by
electrophoresis using Mini-PROTEAN TGXTM gels (Bio-Rad) and detected by
western blotting with the indicated antibodies: MRE11 (1:2000, NB100-142,
Novusbio); PCNA (1:1000, PC10, sc-56), and H3 (1:2000, Ab1791, Abcam).
Analysis of chromosome spreads. After the transfection with speciﬁc siRNAs,
cells were treated with 4 mM HU for 5 h. The genotoxic agent was removed by
washing three times with 1 × PBS and the cells were then released into fresh
medium containing 200 ng ml−1 nocodazole for 16 h. Cells were collected and
swollen with 75 mM KCl for 20 min at 37 °C. Swollen mitotic cells were collected
and ﬁxed with methanol:acetic acid (3:1). The ﬁxing step was repeated two times.
Cells were then dropped onto pre-hydrated glass slides and air-dried overnight.
The following day, slides were mounted with Vectashield medium containing
DAPI. Images were acquired with a microscope (model DMRB; Leica) equipped
with a camera (model DFC360 FX; Leica) and visible chromatid breaks/gaps were
counted.
Flow cytometry. For ﬂow cytometric analysis of EdU/DAPI, cells were labeled for
30 min with 10 μM EdU, collected, and ﬁxed for 15 min with 4% formaldehyde/
PBS. Cells were washed with 1% BSA/PBS, pH 7.4 and permeabilized with 0.5%
saponin/1% PBS. Incorporated EdU was labeled according to the manufacturer’s
instructions (#C-10425; Life Technologies). DNA was stained with 1 μg ml−1 DAPI.
Samples were measured on a Cyan ADP and ATTUNE NXT ﬂow cytometer
(Beckman Coulter) and analyzed by the FlowJo software.
Quantitative real-time PCR. Total RNA was isolated from cells using the Oligotex
mRNA Mini Kit (Qiagen). RNA of 500 ng was used for complementary DNA
(cDNA) synthesis using Transcriptor First Strand cDNA Synthesis Kit (Roche).
Quantitative real-time SYBR-Green-based PCR reactions were performed in
triplicate and monitored with the Light Cycler 480 (Roche) system. The following
primer pairs were used to determine BRCA2 mRNA levels: forward 5′-CACCTCT
GGAGCGGACTTATT-3′; reverse 5′-GCTTTGTTGCAGCGTGTCTT-3′.
The housekeeping gene GAPDH, used as a control, was ampliﬁed with the
following primers: forward 5′-GACATTGTTGCCATCAACGACC-3′; reverse
5′-CCCGTTGATGACCAGCTTCC-3′.
Data availability. The authors declare that all relevant data supporting the ﬁndings
of this study are available within the article and its supplementary information ﬁles
or from the corresponding author upon reasonable request.
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